133 CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicityJonathan Terrett, Demetrios Kalaitzidis, Daniel R. Hostetter et al.|Regular and Young Investigator Award Abstracts|2021Cited by 0